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ORIGINAL ARTICLE
African League Against Rheumatism (AFLAR) preliminary
recommendations on the management of rheumatic diseases
during the COVID-19 pandemic
Richard Oluyinka Akintayo1,26 & Rachid Bahiri2 & Yasser El Miedany3 & Hakeem Olaosebikan4 & Asgar Ali Kalla5 &
Adewale Olukayode Adebajo6 & Angela Nyangore Migowa7 & Samy Slimani8 & Ouma Devi Koussougbo9 &
Ben Abdelghani Kawther10 & Akpabio Akanimo Akpabio11 & Imad Ghozlani12 & Dzifa Dey13 & Waleed A. Hassan14 &
Nimmisha Govind15 & Kavita Makan16 & Abdelgaffar Mohamed17 & Eugene Kalman Genga18 &
Mohamed Khattry Ahmed Ghassem19 & Mohamed Mortada20 & Wafa Hamdi21 & Moudjib O. Wabi22 &
Mohammed Tikly23 & Madeleine Ngandeu-Singwe24 & Christian Scott25
Received: 8 July 2020 /Revised: 11 August 2020 /Accepted: 18 August 2020
# The Author(s) 2020
Abstract
Objectives To develop recommendations for the management of rheumatic and musculoskeletal diseases (RMDs) during the
COVID-19 pandemic.
Method A task force comprising of 25 rheumatologists from the 5 regions of the continent was formed and operated through a hub-
and-spoke model with a central working committee (CWC) and 4 subgroups. The subgroups championed separate scopes of the
clinical questions and formulated preliminary statements of recommendations which were processed centrally in the CWC. The CWC
and each subgroup met by several virtual meetings, and two rounds of voting were conducted on the drafted statements of recom-
mendations. Votes were online-delivered and recommendations were pruned down according to predefined criteria. Each statement
was rated between 1 and 9 with 1–3, 4–6 and 7–9 representing disagreement, uncertainty and agreement, respectively. The levels of
agreement on the statements were stratified as low,moderate or high according to the spread of votes. A statement was retired if it had a
mean vote below 7 or a ‘low’ level of agreement.
Results A total of 126 initial statements of recommendations were drafted, and these were reduced to 22 after the two rounds of voting.
Conclusions The preliminary statements of recommendations will serve to guide the clinical practice of rheumatology across
Africa amidst the changing practices and uncertainties in the current era of COVID-19. It is recognized that further updates to the
recommendations will be needed as more evidence emerges.
Keywords African rheumatology . COVID-19 . DMARD . Rheumatic andmusculoskeletal diseases . Rheumatology
Key Points
• AFLAR has developed preliminary recommendations for the management of RMDs in the face of the COVID-19 pandemic.
• COVID-19 is an unprecedented experience which has brought new concerns regarding the use of some disease-modifying anti-rheumatic drugs
(DMARDs), and these recommendations seek to provide guidelines to African rheumatologists.
•Hydroxychloroquine shortage has become rampant across Africa as the drug is being used as prophylaxis against COVID-19 and this may necessitate
a review of the treatment plan for some patients with RMDs.
• Breastfeeding should continue for as long as possible if a woman is positive for SARS-CoV-2 as there is currently no evidence that the infection can be
transmitted through breast milk.
This article is part of the Topical Collection on Rheumatology in Africa
* Richard Oluyinka Akintayo
r.akintayo@nhs.net
Extended author information available on the last page of the article
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Introduction
Since the advent of the COVID-19 pandemic and the rapid
spread of the disease across the globe, the practice of rheuma-
tology has found itself in the middle of crucial decision
making and widespread service disruption. Across Africa,
the impact of the pandemic is even more noticeable as there
is a wide disparity in the availability and quality of healthcare
services in the different countries and regions of the continent
[1]. Recommendations and practice standards have changed
rapidly in the face of the pandemic, and the potential roles of a
number of disease-modifying anti-rheumatic drugs
(DMARDs) in the management of COVID-19 have come to
the fore.
The leadership of the African League Against Rheumatism
(AFLAR) commissioned a task force to develop recommen-
dations for the management of rheumatic and musculoskeletal
diseases (RMDs) in the unprecedented situation of a continent
faced with COVID-19. The task force had a very short time to
deliver the project. However, the relatively delayed spread of
the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) across the continent a while after other continents
such as Asia, North America and Europe allowed for some
body of evidence to have been developed and recommenda-
tions made by other international rheumatology bodies which
became available for the appraisal of the African team.
Methods
Mandate
The scope of the proposed recommendations was to address
clinical questions encountered on a daily basis by the practic-
ing rheumatologists in Africa in the complex situation where
COVID-19 redefines clinical needs and standards.
Recommendations were proposed to cover the management
of RMDs among adult and paediatric patients in the context of
COVID-19. The task excludes recommendations for the man-
agement of individual RMDs or the treatment of COVID-19.
The lead and membership of the central working committee
(CWC) and subsequently the full membership list of the larger
task force were commissioned by the president of AFLAR to
produce the recommendations within predefined deadlines.
Structure of the task force
A hub-and-spoke model was adopted with the task force
spreading out from the CWC formed by the leads of the four
subgroups as well as the AFLAR president, an executive of
the Pediatric African LeagueAgainst Rheumatism (PAFLAR)
and 2 members of the COVID-19 African Rheumatology
Research Group. The leads of the subgroups were assigned
and delegated with the tasks and the broad themes of each
subgroup were as follows: subgroup 1, risk assessment and
prevention of SARS-CoV-2 infection among patients with
RMDs; subgroup 2, use of usual rheumatological treatments
in patients at risk of SARS-CoV-2 infection; subgroup 3, treat-
ment of patients with RMDs after exposure to known case of
COVID-19; and subgroup 4, management of RMDs in pa-
tients infected with SARS-CoV-2. The subgroup leads were
given the mandate to nominate the membership of their sub-
groups which were to be drawn from all five regions of the
continent. The complete task force was made up of 25 prac-
ticing rheumatologists of which the scope of practice was
adult only in 10, adult and paediatrics in 11 and paediatrics
only in 4. In conjunction with other paediatric rheumatologists
on the task force, the PAFLAR executive on the CWC led an
independent review and representation of the paediatric-
specific recommendations to the CWC.
Timeline
The CWC was set up on June 8, and the first virtual meeting
was held on June 10 by video conferencing. The subsequent
processes and timelines were agreed upon. The return of full
preliminary list of task force membership was attained on
June 12, and the submission of the first set of statements
was completed by June 17. The first round of voting was held
on June 20, while the second round commenced on June 21.
Harmonization of statements and approval of final statements
were completed on June 29.
Background guideline review
Published guidelines and recommendations of international
rheumatology bodies outside Africa on management of
RMDs in the context of COVID-19 were reviewed. This in-
cludes the recently published guidelines of the European
League Against Rheumatism (EULAR), American College
of Rheumatology (ACR), the Australian Rheumatology
Association (ARA), the Asia Pacific League of Associations
for Rheumatology (APLAR) and the National institute for
Health and Care Excellence (NICE) of the UK [2–6].
Relevant aspects were drawn for consideration as one arm of
the recommendations classed as ‘general’. A second arm was
designated ‘Africa-Specific’, and it includes clinical questions
and recommendations that are specific to the settings and pre-
vailing situations in Africa. Each subgroup was tasked with
developing their clinical questions and recommendations
along these two broad divisions.
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Target audience
The primary target audience are practicing rheumatologists in
Africa. This includes rheumatologists managing adult, paedi-
atric or both categories of patients. The focus excludes pa-
tients, other physicians or policy-makers. However, recom-
mendations covering advice to patients which are to be deliv-
ered by the rheumatologist are included.
Literature review
It was agreed that there is currently an insufficient body of
evidence to conduct a meaningful systematic literature review.
In addition, the short working timeline available to the task
force precluded further delays. However, a limited non-
systematic literature review was undertaken to support the
largely expert opinion-based process. This was conducted be-
tween the 4 subgroup leads and harmonized in the CWC.
Processing of clinical questions and
recommendations
Each subgroup was tasked to develop the clinical questions
according to the theme of their subgroup and make prelimi-
nary recommendations to be submitted to the central working
committee towards the first round of votes. The four sub-
groups turned in a total of one hundred and twenty-six prelim-
inary statements of recommendation which were processed
centrally. Overlaps, duplication and out-of-scope recommen-
dations were removed or amended, and the first list for the first
round of voting was agreed upon by the CWC. At the end of
the first round of voting, there were twenty-four statements of
recommendation. These were processed further into the sec-
ond round of voting which led to the final agreement on
twenty-two statements.
Voting process
Live online-delivered voting was done in two stages that were
strictly time limited. All members of the task force were invit-
ed to participate and were pre-informed of the time of opening
and closure of each round of votes. Unique access links were
sent out, and anonymous votes were gathered and processed.
Comments on re-phrasing, potential ambiguity, unidentified
overlaps and so on were gathered regarding each statement at
the same time in the voting process. Only the members of the
task force who treat either both adults and children or children
only voted on the statements that are specific to paediatric
rheumatology.
Rating
Each statement was rated between 1 and 9 with 1 being ‘com-
plete disagreement’ and 9 being ‘complete agreement’.
Generally, 1–3, 4–6 and 7–9 represented disagreement, uncer-
tainty and agreement, respectively. There was no requirement
to vote on all statements, and the members were encouraged to
abstain if they felt that a statement fell outside their area of
expertise. Therefore, an ‘uncertainty’ vote represented ‘un-
convinced about the veracity of the recommendation’ and ex-
cludes ‘unsure of the current best practice in this context’. All
statements were allowed for the entry of comments which
were reviewed by the CWC after each round of voting. In
the second round of votes, the members were further urged
to leave comments wherever they voted a disagreement. This
enabled the panel to identify an instance of misinterpretation
of statement and invalidate the vote on that statement.
Predefined parameters
The levels of agreement on each statement of recommenda-
tion were defined as ‘high’ if after the second round of votes,
all votes on a statement fell into the agreement bracket; ‘low’
if at least one vote fell into each of the disagreement and
uncertainty bracket or two or more fell into disagreement
bracket; and ‘moderate’ for all other combinations. A state-
ment was retired if it had a mean vote below 7 or a ‘low’ level
of agreement.
Results
A total of twenty-two recommendations were generated, and a
breakdown is presented in Table 1. Below is a brief explana-
tion of each statement and the considerations leading to their
formation.
Statement 1 There is currently no evidence to say that patients
with RMDs or on DMARDs are more prone to contracting
SARS-CoV-2; therefore, the normal medications for various
rheumatic diseases should be continued as indicated.
The risk factors for getting infected with the novel corona-
virus are similar for patients with RMDs as for the general
populace, and these include older age and co-morbidities such
as hypertension and diabetes [2, 7]. Patients with RMDs have
not been identified to bemore prone to developing COVID-19
than people without RMDs, and this seems to be similar for
the previous outbreaks of earlier corona viruses such as the
severe acute respiratory syndrome coronavirus (SARS-CoV)
and the Middle East respiratory syndrome coronavirus
(MERS-CoV) [8, 9]. Mixed results have been reported with
patients on prednisolone of more than 10 mg per day as well
as disease-modifying agents such as anti-TNF and other
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biologics. Also, conventional DMARDs and NSAIDs have
not been identified to increase the odds of infection or hospi-
talization [10]. So far, it would appear that there is no definite
evidence to date that ongoing treatments for RMDs confer
added risks of infection with SARS-CoV-2 [11, 12].
Statement 2 Patients should be routinely advised to observe
regular infection-prevention practices against SARS-CoV-2
such as social distancing, frequent handwashing and wearing
of face covering in public places.
Standard infection-prevention practices should be frequent-
ly communicated and reinforced at every opportunity to the
Table 1 Breakdown of statements of recommendations
S/
N
Statements Mean rank
±SD
Level of
agreement
1 Statement 1: There is currently no evidence to say that patients with RMDs or on DMARDs are more prone to
contracting SARS-CoV-2; therefore, the normal medications for various rheumatic diseases should be continued
as indicated
8.8 ± 0.4 H
2 Statement 2: Patients should be routinely advised to observe regular infection-prevention practices against
SARS-CoV-2 such as social distancing, frequent hand washing and wearing of face covering in public places
9.0 ± 0 H
3 Statement 3: Patients should be advised to avoid using medicinal products with unproven efficacy against
COVID-19. Such products could include herbal preparations, orthodox medicines, various supplements and
complementary medications
8.7 ± 0.8 M
4 Statement 4: In a patient without COVID-19, it is safe to initiate or maintain the use of NSAIDs for RMDs where
indicated
8.6 ± 0.5 H
5 Statement 5: In a patient without COVID-19, oral or parenteral glucocorticoids may be used as indicated at the
appropriate dose including pulse doses where necessary
8.9 ± 0.4 H
6 Statement 6: Anti-malarials such as HCQ and CQ do not protect against SARSCoV-2, and as such, patients on HCQ
or CQ for RMDs should be advised to observe necessary precautions to prevent infection
8.8 ± 0.5 H
7 Statement 7:Where HCQ scarcity is being experienced, rheumatologists may consider using alternative csDMARDs
for patients with rheumatoid arthritis
8.4 ± 0.9 M
8 Statement 8: Where possible, the use of subcutaneous formulations of bDMARDs and bsDMARDs should be
considered instead of IV infusions to limit patients’ attendance to the hospital
8.8 ± 0.5 H
9 Statement 9: ACEIs and ARBs should not be routinely discontinued in patients with RMDs at risk of COVID-19 8.2 ± 1.2 M
10 Statement 10: Patients with stable RMDs should have their vaccination against influenza and pneumococci updated 8.8 ± 0.5 H
11 Statement 11: Rheumatologists should reduce patients’ hospital attendances by considering less frequent blood
monitoring for DMARDs among stable patients, longer prescription periods and virtual clinics
8.9 ± 0.4 H
12 Statement 12: RMD patients on glucocorticoids who have been exposed to SARS-CoV-2 should continue their
glucocorticoids at the lowest effective dose for maintaining disease control
8.6 ± 0.66 H
13 Statement 13: In patients who have been exposed to SARS-CoV-2 but are asymptomatic, continue anti-osteoporosis
treatments including vitamin D and calcium supplementation
8.7 ± 0.5 H
14 Statement 14: Following exposure to SARS-CoV-2 infection, continue PJP prophylaxis in a patient who is already
on it
8.3 ± 1.0 M
15 Statement 15: Regardless of recent exposure to SARS-CoV-2, ACEIs and ARBs may be initiated or increased in a
patient with RMD if indicated
8.1 ± 1.2 M
16 Statement 16: Regardless of recent exposure to SARS-CoV-2, intra-articular steroid administration may be
undertaken if indicated with the use of appropriate personal protective equipment (PPE)
8.8 ± 0.4 H
17 Statement 17: In an RMD patient with confirmed or presumed COVID-19, ongoing glucocorticoid treatment should
not be stopped but should be maintained at the lowest effective dose
8.5 ± 0.5 H
18 Statement 18: In an RMD patient with confirmed or presumed COVID-19, unless specifically indicated, routine
stoppage of NSAIDs, analgesics, ACEIs or ARB is not required.
8.4 ± 0.6 H
19 Statement 19: Each rheumatology service should consider providing a helpline number to patients to use or for their
doctors to use to seek rheumatological advice should they develop COVID-19.
8.8 ± 0.5 H
20 Statement 20: There is currently no proof that SARS-CoV-2 infection is transmitted through breastfeeding, thus
breastfeeding may be continued while observing personal hygiene precautions if a lactating woman has tested
positive for SARS-CoV-2 infection.
7.4 ± 1.8 M
21 Statement 21: In the event that a lactating mother with COVID-19 is too unwell to breastfeed the child, expressed
breast milk or formula feeds should be considered and these should be prepared using hygienic practices as
recommended by government and regulatory bodies of the given region.
7.0 ± 1.7 M
22 Statement 22: Among paediatric patients with suspected SARS-CoV-2 infection who have negative nasopharyngeal
PCR test, PCR test on stool samples should be considered to help confirm the diagnosis.
7.0 ± 1.7 M
SD standard deviation, DMARD disease-modifying anti-rheumatic drug, RMD rheumatic and musculoskeletal disease, SARS-CoV-2 severe acute
respiratory syndrome coronavirus 2, NSAID non-steroidal anti-inflammatory drug, COVID-19 coronavirus disease 2019, HCQ hydroxychloroquine,
CQ chloroquine, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, bDMARD biologic disease-modifying anti-rheumatic drug,
bsDMARD biosimilar disease-modifying anti-rheumatic drug, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, PCR
polymerase chain reaction, H high, M moderate
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patients according to the recommendations in each member
country of AFLAR [2, 3]. This was widely agreed upon by all
members of the task force in recognition that there are some
differences between the national policies of the member coun-
tries against COVID-19. Components of the rheumatologist’s
advice should include regular and adequate hand washing,
social distancing, avoiding touching the face and coughing
into the elbow [13]. Other specific infection-prevention advice
may be relevant to the individual patient scenario or the pre-
vailing local guidelines.
Statement 3 Patients should be advised to avoid using medic-
inal products with unproven efficacy against COVID-19. Such
products could include herbal preparations, orthodox medi-
cines, various supplements and complementary medications.
It was recognized that a long list can be made of various
unproven remedies which have attained different levels of
fame in the media since the onset of COVID-19 pandemic.
While this is not limited to Africa, the continent certainly has
its fair share of promoted orthodox, herbal and complementa-
ry medicines of unproven efficacy against COVID-19. Some
of these have been shown to be associated with some risks in
earlier reports [14, 15].
Statement 4 In a patient without COVID-19, it is safe to
initiate or maintain the use of NSAIDs for RMDs where
indicated.
For many patients who depend on regular NSAID use for
managing their RMDs, routine withdrawal of such treatment
may be counterproductive to the goal of care. This is particu-
larly noteworthy as exposure to NSAIDs has not been shown
to increase the risk of infection with SARS-CoV-2. Whereas
NSAIDs should generally be used in the lowest effective dose,
the use in patients who go on to develop COVID-19 should be
based on a favourable risk-benefit ratio [3, 16]. Certainly,
there is currently no evidence-backed contraindication to the
use of NSAIDs in the patient who is at risk of COVID19 [17].
Statement 5 In a patient without COVID-19, oral or paren-
teral glucocorticoids may be used as indicated at the appro-
priate dose including pulse doses where necessary.
It is recognized that the fear of glucocorticoid use in the era
of COVID-19 may expose patients with organ-threatening
diseases such as the vasculitides and aggressive connective
tissue diseases to greater risks if appropriate interventions
using the required immunosuppressive agents are not prompt-
ly adopted. Undoubtedly, patients with these conditions may
face short-term risks of major organ damage or mortality with-
out appropriate treatment [18]. Therefore, in the context of
these severe diseases, the appropriate dose of glucocorticoids
including high and pulse doses may be unavoidable [3].
Statement 6 Anti-malarials such as HCQ and CQ do not
protect against SARSCoV-2, and as such, patients on HCQ
or CQ for RMDs should be advised to observe necessary
precautions to prevent infection.
Despite the in vitro anti-viral activities of HCQ and CQ
which have been reported in various studies, these anti-
malaria drugs have not been shown to prevent SAS-CoV-2
infection and patients with SLE on long-term treatment with
anti-malarial drugs have not been shown to be spared from the
infection or developing severe diseases [19]. The task force
recognized that there have been unsubstantiated suggestions at
the beginning of the pandemic that the widespread use of anti-
malarial drugs in Africa may be contributing to the delayed
spread of the virus on the continent.
Statement 7Where HCQ scarcity is being experienced, rheu-
matologists may consider using alternative csDMARDs for
patients with rheumatoid arthritis.
The recent pan-African survey through the network of the
COVID-19 African Rheumatology Study Group has shown
that shortage of HCQ was being experienced in more than
60% of rheumatologists’ services across the continent [1].
Therefore, for patients with rheumatoid arthritis, it was agreed
that alternative DMARDs may be considered where appropri-
ate. The task force recognized that some patients on triple
therapy with stable disease may be able to continue with two
csDMARDs without suffering flare ups.
Statement 8 Where possible, the use of subcutaneous formu-
lations of bDMARDs and bsDMARDs should be considered
instead of IV infusions to limit patients’ attendance to the
hospital.
The availability of biologic and biosimilar agents is highly
varied across the continent of Africa. Many countries do not
have access to any biosimilar drugs, and in others, the subcu-
taneous formulations of existing specific intravenously ad-
ministered biologics are not available. It was agreed that rheu-
matologists will have to consider the options within the limit
of the available agents in their country. However, the driving
goal of limiting in-patient hospital visits for infusion adminis-
tration should be pursued wherever possible.
Statement 9 ACEIs and ARBs should not be routinely
discontinued in patients with RMDs at risk of COVID-19.
Whereas there is no evidence to suggest that ACEIs or
ARBs increase the risk of SARS-CoV-2 infection, a large
population-based study has revealed that the prevalence of
use of these agents among patients with COVID19 is
higher than in the general populace [20]. This is probably
indicative of a higher prevalence of cardiovascular co-
morbidities such as hypertension among patients with
clinical and severe COVID-19, and this category of pa-
tients is also more likely to be on treatment with these
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drugs [20]. However, a study from the USA showed an
almost 40% reduction in the risk of hospitalization among
elderly patients with hypertension treated with ACEIs but
not among those treated with ARBs [21]. The recommen-
dation of both the American Heart Association and the
European Society for Cardiology is to sustain treatment
with these drugs in patients on them [22, 23]. This is also
the recommenda t ion of the French Soc ie ty of
Rheumatology [17].
Statement 10 Patients with stable RMDs should have their
vaccination against influenza and pneumococci updated.
The administration of influenza and pneumococcal vac-
cines to stable patients without COVID-19 was generally
agreed upon.While it is not known if being vaccinated against
influenza could reduce the severity of COVID-19, certainly,
reducing this risk may cut down the potential confusion with
COVID-19 among some patients [2, 24]. The task force rec-
ognized that national policies on vaccination differ among the
member countries of AFLAR; members however agree that
the ongoing pandemic should not reduce the use and admin-
istration of these vaccines for eligible patients.
Statement 11 Rheumatologists should reduce patients’ hospi-
tal attendances by considering less frequent blood monitoring
for DMARDs among stable patients, longer prescription pe-
riods and virtual clinics.
Wherever routine blood monitoring for DMARDs requires
the attendance of patients to the hospital, reducing the fre-
quency of laboratory investigations among stable patients will
likely be of benefit [3]. This may imply re-organizing services
and optimizing the line of communication between the
healthcare service and the patient. Due to the increasing rec-
ognition of in-hospital transmission of SARS-CoV-2, limiting
attendance will likely serve to reduce the anxiety of the
healthcare workers and the patients [18]. As many patients
with RMDs also have co-morbidities that put them at higher
risk of severe COVID-19 such as metabolic syndrome, car-
diovascular diseases and advanced age, it is important to ex-
plain this risk to patients and help them understand the pur-
pose of reducing face-to-face interactions [25].
Statement 12 RMD patients on glucocorticoids who have
been exposed to SARS-CoV-2 should continue their glucocor-
ticoids at the lowest effective dose for maintaining disease
control.
Recognizing the risk of adrenal suppression and the uncer-
tain benefit of aggressive steroid tapering or withdrawal led to
the task force agreeing on sustaining glucocorticoid treatments
albeit at doses not more than required to keep treated condi-
tions controlled. This seems to align with the recommenda-
tions of other international associations of rheumatology [2–4,
17].
Statement 13 In patients who have been exposed to SARS-
CoV-2 but are asymptomatic, continue anti-osteoporosis
treatments including vitamin D and calcium supplementation.
The task force noted that the widespread disruption of
service may put osteoporosis service on a lower rung of
priority than usual. In situations like this, efforts should
be made, and patients are advised to sustain the ongoing
use of osteoporosis prophylaxis or treatment in order to
prevent the potentially devastating impacts of fragility
fractures [26]. While COVID-19 poses a veritable threat
to the African population, the management of other chron-
ic health conditions should not suffer unintended conse-
quences such as prolonged neglect resulting in mounting
morbidity and mortality [27]. Hospital-administered treat-
ments such as intravenous zolendronate and the training
of self-injection of subcutaneous agents such as
denosumab and teriparatide may face delays. It is not
known for certain how long a delay of each agent is ac-
ceptable, but rheumatologists should assist the patients in
preventing long treatment gaps wherever possible.
Statement 14 Following exposure to SARS-CoV-2 infection,
continue Pneumocystis jirovecii pneumonia (PJP) prophylax-
is in a patient who is already on it.
The appropriate use of PJP prophylaxis before the advent
of the novel SARS-CoV-2 should not stop in the current pan-
demic. It is agreed that the potential confusion that may result
from the presentations of both diseases can lead to avoidable
clinical dilemmas especially as the impact of superimposed
PJP on COVID-19 has not been determined. Anecdotal re-
ports have now shown PJP pneumonia mimicking COVID-
19, and recent guidelines have advocated the sustenance of
PJP prophylaxis [2, 28].
Statement 15 Regardless of recent exposure to SARS-CoV-2,
ACEIs and ARBs may be initiated or increased in a patient
with RMD if indicated.
Despite the fear that has been associated with the use of
ACEIs and ARBs regarding SARS-CoV-2 infection, there has
not been any evidence that the use of these drugs makes prov-
en infection worse. The task force agrees that it is logical to
sustain treatment with these drugs among patients who have
ongoing indications for their use except if there are other clin-
ical reasons for discontinuation. This is similar to the position
of other professional rheumatology bodies in Europe and
America [3, 17].
Statement 16 Regardless of recent exposure to SARS-CoV-2,
intra-articular steroid administration may be undertaken if
indicated with the use of appropriate personal protective
equipment (PPE).
Where indicated, there is no evidence to avoid administer-
ing intra-articular steroids for patients where this is the best
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option of care after weighing the risk of hospital attendance.
However, standard procedures regarding the use of personal
protective equipment should be observed to limit the risk of
transmission of SARS-CoV-2 infection between healthcare
professionals and patients where such procedures are deemed
justified [18].
Statement 17 In an RMD patient with confirmed or presumed
COVID-19, ongoing glucocorticoid treatment should not be
stopped but should be maintained at the lowest effective dose.
It is agreed that the abrupt cessation of ongoing long-term
glucocorticoid treatment in patients who have been on it in the
long term before developing COVID-19 serves to cause more
problems than prevent unproven worse outcome. This is sim-
ilar to the recommendation of the ACR and EULAR, and it
was agreed that advising the patient in advance regarding the
use of glucocorticoids in the event of developing COVID-19
will help to prepare them properly [2–4]. In addition, a new
trial has shown that dexamethasone reduces 28-day mortality
among patients receiving oxygen or onmechanical ventilation
[29].
Statement 18 In an RMD patient with confirmed or presumed
COVID-19, unless specifically indicated, routine stoppage of
NSAIDs, analgesics, ACEIs or ARB is not required.
Strictly speaking, the new diagnosis of COVID-19 should
not be taken as an indication for discontinuation of analgesics,
NSAIDs, ACEIs or ARBs. This recommendation is based on
the lack of evidence of a worse outcome among patients on
these treatments, where they are sustained throughout the
management of their COVID-19 symptoms.
Statement 19 Each rheumatology service should consider
providing a helpline number to patients to use or for their
doctors to use to seek rheumatological advice should they
develop COVID-19.
Various patterns of anxieties have been shown in the recent
African survey of rheumatologists and their perception of their
patients [1]. Some of these can be allayed in the patient by
keeping an open line of communication and maintaining easy
and rapid access to reaching the rheumatologist helpline for
advice. In this period, it will not be unexpected for patients to
be unusually anxious, and this state may be helped by having
reliable access to guidance regarding the management of their
RMD treatments and queries around their RMDs [18].
Statement 20 There is currently no proof that SARS-CoV-2
infection is transmitted through breastfeeding; thus,
breastfeeding may be continued while observing personal hy-
giene precautions if a lactating woman has tested positive for
SARS-CoV-2 infection.
The nucleic acid of the SARS-CoV-2 virus has not been
detected in breast milk, and it stands reasonable that the
unlikely risk of transmission is much lower than the known
benefits of continued breastfeeding. However, observation of
standard infection-prevention practices should be advised
[30]. Rooming-in may be feasible, and direct breastfeeding
is advisable in a woman with suspected or confirmed
COVID-19 [31]. The World Health Organization recom-
mends continuing breastfeeding for as long as possible regard-
less of a mother’s COVID-19 status while practicing standard
hygiene methods and taking respiratory precautions including
wearing a mask [13].
Statement 21 In the event that a lactating mother with
COVID-19 is too unwell to breastfeed the child, expressed
breast milk or formula feeds should be considered, and these
should be prepared using hygienic practices as recommended
by government and regulatory bodies of the given region.
Where the clinical status of the mother will make direct
breastfeeding impractical, expressed breast milk is agreed on
as an ideal feeding option, and this will not require pasteuri-
zation [31]. Formula feeding is an acceptable alternative if
breastfeeding is not possible. It was recognized that
preventing women in rural Africa from breastfeeding their
children is likely to be associated with significant deleterious
economic and health impacts and there is currently no evi-
dence to advise exercising caution in this regard as long as
hygienic practices are followed.
Statement 22 Among paediatric patients with suspected
SARS-CoV-2 infection who have negative nasopharyngeal
PCR test, PCR test on stool samples should be considered to
help confirm the diagnosis.
It may well be that relying only on the nasopharyngeal
swab test for the diagnosis of COVID-19 in children will
potentially lead to significant under-diagnosis, and, as such,
it is agreed that faecal PCR test may be an additional screening
method. Indeed, emerging data seem to suggest the possibility
of faecal transmission as an additional route [32]. This may be
from environmental contamination, a risk that is likely higher
in both rural African communities and in urban slums. As
children of all ages have been shown to develop COVID-19
without any gender disparity, healthcare professionals would
do well to not exercise prolonged inertia in embarking upon
appropriate testing of these patients, but it is advisable to limit
the number of parents or family members attending with the
patient to the barest minimum [18].
Discussion
In the unprecedented experience of a world grappling with
COVID-19, the task force was faced with a need to deliver a
project backed by a limited amount of high-quality evidence.
Certainly, this is a circumstance which rheumatology in
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Africa and beyond is not familiar with and which the rest of
the world is currently struggling with as well. Preliminary
preparation in the run up to setting out with this project in-
cluded the consideration for commissioning a research and
development company to conduct a systematic literature re-
view of evidence in the shortest time possible. It soon became
clear that the scanty amount and low quality of existing evi-
dence on various relevant clinical questions as well as the
lengthy duration needed for its execution made it an unworthy
venture to proceed with. While a number of useful insights
were drawn from the recommendations of national and inter-
national rheumatology societies outside Africa, aspects that
are specific to paediatric rheumatology were excluded in most
of these [2–4, 17]. However, the structure of AFLAR and the
gradually growingmembership of the PAFLAR usefully iden-
tified the need to work together to produce a common docu-
ment in view of potential substantial overlaps in the relevant
aspects of recommendation for adults and children in the era
of COVID-19. The other peculiarity is the wide disparity in
the structures of rheumatology and the entire healthcare ser-
vices of the various countries covered by AFLAR.
A recognition of these variations meant that some flexibil-
ity is required with interpretation of some of these recommen-
dations in the context of the prevailing local policies.
Similarly, the relevance of some of the recommendations
may succumb to the limit of available options of DMARDs
and their formulations in some countries. Furthermore, the
standard vaccination practices in some countries may dictate
a contextual interpretation of the recommendation on influen-
za and pneumococcal vaccinations as provided in this docu-
ment. It is recognized that with the emergence of more high-
quality data over time, the need for current recommendations
to evolve is acknowledged, and subsequent updated versions
of these preliminary recommendations will be produced.
In its history, this is the first time that the AFLAR convened
an emergency task force to deliver a formal draft of recom-
mendations within a very short time in circumstances that
have not been experienced by any member of the task force
before. The virtual convening, execution and delivery of the
project with seamless efficacy within the limit of resources
and published evidence, however, signal a future of more
possibilities in executing daunting tasks under difficult cir-
cumstances and tight schedules. Whereas there are still unan-
swered questions about the management of RMDs in the
world of COVID-19, we identify that there are endless needs
for research and service improvement to deliver the best care
to the African patients. The task force agreed to target rheu-
matologists and not policy-makers, other physicians or pa-
tients directly. However, relevant aspects of advice suitable
for patients are directed towards the rheumatologist for deliv-
ery to the African patients.
Certainly, patient education is crucial in the proper delivery
of the safety practices and best approaches to dealing with
RMDs in this precarious time of the pandemic. The coalition
of national rheumatology societies within AFLAR will be a
cornerstone in cascading the preliminary recommendations
through their networks and working together to deliver sub-
sequent updates with even more answers to clinical questions
of wider pan-African spread. The immediate future calls for a
continuation of seeking answers to various questions around
the care for RMDs in the world of COVID-19, and it has
become imperative that the lessons learnt so far be thought-
fully processed going forward.
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